公开(公告)号：US20240358811A1

公开(公告)日：2024-10-31

申请号：US18526557

申请日：2023-12-01

Applicant: The Brigham and Women's Hospital, Inc.

Inventor： Gerald B. Pier ,  Colette Cywes Bentley ,  David Skurnik

IPC: A61K39/085 ,  A61K31/715 ,  A61K39/00 ,  A61K39/002 ,  A61K39/015 ,  A61K39/02 ,  A61K39/04 ,  A61K39/07 ,  A61K39/08 ,  A61K39/09 ,  A61K39/095 ,  A61K39/385 ,  A61K47/64 ,  C07K16/12 ,  C07K16/14 ,  C07K16/20 ,  C08B37/00 ,  G01N33/569

CPC classification number: A61K39/085 ,  A61K31/715 ,  A61K39/0002 ,  A61K39/002 ,  A61K39/015 ,  A61K39/0208 ,  A61K39/025 ,  A61K39/04 ,  A61K39/07 ,  A61K39/08 ,  A61K39/092 ,  A61K39/095 ,  A61K39/107 ,  A61K39/385 ,  A61K47/6415 ,  A61K47/646 ,  C07K16/12 ,  C07K16/14 ,  C07K16/20 ,  C08B37/0006 ,  G01N33/569 ,  G01N33/56938 ,  A61K2039/505 ,  A61K2039/572 ,  A61K2039/6031 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/31 ,  G01N2400/00 ,  G01N2469/10

Abstract: The invention relates, in part, to the use of compositions of poly N-acetylated glucosamine (PNAG) and antibodies specific to PNAG in the prevention and treatment of infections by certain PNAG-positive pathogens and in detection (including diagnostic) methods.

公开(公告)号：US20240335521A1

公开(公告)日：2024-10-10

申请号：US18591479

申请日：2024-02-29

Applicant: Vaxcyte, Inc.

Inventor： Christopher Iain GRAINGER ,  Sandrine BARBANEL ,  Shashwati Ujwalkumar ATWE

IPC: A61K39/09 ,  A61K39/00 ,  A61K39/095 ,  A61K39/102 ,  A61K39/39 ,  A61K47/02

CPC classification number: A61K39/092 ,  A61K39/095 ,  A61K39/102 ,  A61K39/39 ,  A61K47/02 ,  A61K2039/55505 ,  A61K2039/6031 ,  A61K2039/6087

Abstract: The present disclosure provides stabilized vaccine compositions that resist the formation of unsuitable adjuvant flocculant or aggregates. The present disclosure further provides methods of using such compositions to induce immune responses against infections in subjects.

公开(公告)号：US12109261B1

公开(公告)日：2024-10-08

申请号：US18670803

申请日：2024-05-22

Applicant: THE SCRIPPS RESEARCH INSTITUTE

Inventor： Linling He ,  Jiang Zhu ,  Ian A. Wilson ,  Yi-Zong Lee

IPC: C07K14/005 ,  A61K39/12 ,  A61K39/145 ,  C07K1/00 ,  C07K14/11 ,  A61K39/00

CPC classification number: A61K39/145 ,  C07K14/005 ,  A61K2039/6031 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16222 ,  C12N2760/16234 ,  C12N2760/16322 ,  C12N2760/16334

Abstract: The present invention provides novel engineered influenza hemagglutinin (HA) proteins, related polynucleotide sequences, and vaccine compositions including nanoparticle compositions. Relative to a wildtype HA protein, the engineered HA proteins are stabilized via substitutions of one or more conserved residues in the HA2 ectodomain with hydrophobic residues. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating influenza viral infections.

公开(公告)号：US20240299523A1

公开(公告)日：2024-09-12

申请号：US18660419

申请日：2024-05-10

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Leena Shriram Bagle ,  Amardeep Singh Bhupender Bhalla ,  Miguel Angel Garcia ,  Lei Hu ,  Lakshmi Khandke ,  Avvari Krishna Prasad ,  Cindy Xudong Yang

IPC: A61K39/09 ,  A61K39/00 ,  A61K39/39

CPC classification number: A61K39/092 ,  A61K39/39 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/55505 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/70

Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

公开(公告)号：US20240294579A1

公开(公告)日：2024-09-05

申请号：US18616134

申请日：2024-03-25

Applicant: CureVac SE

Inventor： Thomas KRAMPS ,  Margit SCHNEE ,  Daniel VOSS ,  Benjamin PETSCH

IPC: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/155 ,  A61K48/00 ,  C07K16/10 ,  C12N7/00

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  C07K16/1027 ,  C12N7/00 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/6031 ,  A61K48/00 ,  C07K2317/24 ,  C12N2760/18534

Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

公开(公告)号：US20240287146A1

公开(公告)日：2024-08-29

申请号：US18499938

申请日：2023-11-01

Applicant: AMSILK GmbH ,  Ludwig-Maximilians-Universitat Munchen ,  Universitat Bayreuth

Inventor： Lin ROMER ,  Ute SLOTTA ,  Julia ENGERT ,  Gerhard Winter ,  Matthias Lucke ,  Thomas Scheibel

IPC: C07K14/435 ,  A61K38/00 ,  A61K39/00 ,  A61K39/385 ,  A61K47/42 ,  A61K47/64 ,  A61K47/65 ,  A61P35/00 ,  C12N15/62

CPC classification number: C07K14/43518 ,  A61K39/385 ,  A61K47/42 ,  A61K47/646 ,  A61K47/65 ,  A61P35/00 ,  C07K14/43586 ,  C12N15/62 ,  A61K38/00 ,  A61K2039/6031 ,  A61K2039/627 ,  C07K2319/40 ,  C07K2319/50

Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.

公开(公告)号：US20240226262A9

公开(公告)日：2024-07-11

申请号：US18467682

申请日：2023-09-14

Applicant: Prime Bio, Inc.

Inventor： Bal Ram Singh

IPC: A61K39/02 ,  A61K39/00 ,  A61K39/08 ,  A61K39/395 ,  A61P31/04 ,  C07K14/19 ,  C07K14/235 ,  C07K14/33 ,  C07K14/34 ,  C12N15/62 ,  C12N15/66 ,  C12N15/70

CPC classification number: A61K39/099 ,  A61K39/0018 ,  A61K39/08 ,  A61K39/39525 ,  A61P31/04 ,  C07K14/19 ,  C07K14/235 ,  C07K14/33 ,  C07K14/34 ,  C12N15/62 ,  C12N15/66 ,  C12N15/70 ,  A61K2039/542 ,  A61K2039/6031 ,  A61K2039/622

Abstract: The present invention describes a second-generation tetanus toxoid vaccine and a process for the preparation thereof, comprising the steps of: inducing an E. Coli culture OD 600=0.5 by adding 0.2 mM IPTG; growing the culture at 14-16° C. for 14 to 20 hours; suspending the culture in 25 mM phosphate buffer containing 200 mM sodium chloride; adding 1% of triton-X-100 to the phosphate buffer, and adding the buffer to the culture; sonicating the culture for a period of 3 minutes (at 5 sec on/off pulse) at 4° C. on cold beads; centrifuging the culture for 60 to 90 minutes; collecting and purifying a supernatant using Ni-NTA affinity column with an eluant; and combining the supernatant into a pool with contaminated bands and concentrating using Centriprep-30 centrifuge filters (30 kDa pores).

公开(公告)号：US12016913B2

公开(公告)日：2024-06-25

申请号：US17474561

申请日：2021-09-14

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Leena Shriram Bagle ,  Amardeep Singh Bhupender Bhalla ,  Miguel Angel Garcia ,  Lei Hu ,  Lakshmi Khandke ,  Avvari Krishna Prasad ,  Cindy Xudong Yang

IPC: A61K39/00 ,  A61K39/09 ,  A61K39/39

CPC classification number: A61K39/092 ,  A61K39/39 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/55505 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/70

Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

公开(公告)号：US20240181077A1

公开(公告)日：2024-06-06

申请号：US18547242

申请日：2022-02-24

Applicant: UNIWERSYTET JAGIELLONSKI

Inventor： Jonathan HEDDLE ,  Artur BIELA ,  Yusuke AZUMA ,  Antonina NASKALSKA ,  Kinga BORZECKA-SOLARZ ,  Jan ROZYCKI ,  Izabela STUPKA

IPC: A61K47/69 ,  A61K39/385 ,  A61K41/00

CPC classification number: A61K47/6949 ,  A61K39/385 ,  A61K41/0042 ,  A61K2039/6031

Abstract: The present invention provides an artificial TRAP-cage comprising a selected number of TRAP rings and encapsulated therein a guest cargo.

公开(公告)号：US20240150412A1

公开(公告)日：2024-05-09

申请号：US18452698

申请日：2023-08-21

Applicant: CLEARB THERAPEUTICS LTD. ,  MELBOURNE HEALTH

Inventor： Renae Walsh ,  Stephen Locarnini ,  Hans Netter ,  Ronald Farquhar

IPC: C07K14/005 ,  A61K39/29 ,  A61P31/20 ,  C12N7/00

CPC classification number: C07K14/005 ,  A61K39/292 ,  A61P31/20 ,  C12N7/00 ,  A61K2039/6031

Abstract: Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).